Our study suggests that increasing SCFA levels through pre- or probiotics, or use of HDAC inhibitors such as SAHA may not only be beneficial in improving intestinal barrier dysfunction, but may also lead to a more favorable gut hormone balance that may reduce appetite signaling in patients with obesity. The gene discussed is HDAC9; the disease is obesity due to melanocortin 4 receptor deficiency.